ClinicalTrials.Veeva

Menu

Augmentation of Limb Perfusion With Contrast Ultrasound

Oregon Health & Science University (OHSU) logo

Oregon Health & Science University (OHSU)

Status

Enrolling

Conditions

Peripheral Arterial Disease

Treatments

Device: Ultrasound

Study type

Interventional

Funder types

Other

Identifiers

NCT03195556
IRB00017343

Details and patient eligibility

About

Our laboratory has discovered that ultrasound (US) imaging together with clinically approved microbubble ultrasound contrast agents can augment limb tissue perfusion. These observations have been made in mice with and without peripheral artery disease (PAD), and also in humans where high power contrast enhanced ultrasound (CEU) was used to measure perfusion but was found also to augment perfusion by almost 2-fold. The latter human studies were performed with ultrasound protocols designed for perfusion imaging and not for flow augmentation. In this study, we will measure the degree to which limb perfusion is augmented with specific therapeutic CEU settings that are still within the FDA-approved limits with regards to US power and contrast dosing.

Enrollment

30 estimated patients

Sex

All

Ages

19 to 99 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age ≥18 y.o.
  • For PAD subjects: known history of unilateral or bilateral PAD diagnosed by reduced ankle-brachial index or angiography and a Rutherford symptom class of 4-6.

Exclusion criteria

  1. Major medical illness other than PAD affecting the limb (muscle disease, blood diseases that influence flow or rheology, severe heart failure [NYHA class IV or LVEF <30%]).
  2. Pregnant or lactating females
  3. Hypersensitivity to any ultrasound contrast agent
  4. Known atrial septal defect or large right to left shunt.
  5. Hemodynamic instability (hypotension with systolic BP <90 mm Hg, need for vasopressors)
  6. Evidence for ongoing myocardial ischemia
  7. For normal controls, any known structural non-arrhythmic cardiovascular disease (coronary artery disease, heart failure, moderate or greater valve disease).

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

30 participants in 2 patient groups

Healthy subjects
Experimental group
Description:
Low-power contrast ultrasound perfusion imaging and measurement of ABI and TBI will be performed before and after a 15 min high-power ultrasound cavitation therapy with intermittent ultrasound and intravenous infusion of microbubbles.
Treatment:
Device: Ultrasound
Peripheral Artery Disease
Experimental group
Description:
Low-power contrast ultrasound perfusion imaging and measurement of ABI and TBI will be performed before and after a 15 min high-power ultrasound cavitation therapy with intermittent ultrasound and intravenous infusion of microbubbles.
Treatment:
Device: Ultrasound

Trial contacts and locations

1

Loading...

Central trial contact

Jonathan R Lindner, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems